Purpose-built for personalized precision
Exquisite sensitivity
Haystack MRD™
Minimal residual disease (MRD) testing demands the most sensitive ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after definitive surgery.
Residual disease detection
Go beyond standard risk assessment for adjuvant chemotherapy guidance to confidently treat the right person at the right time.
Treatment response monitoring
Disease recurrence surveillance
Transformative precision
Dive deeper
Haystack Oncology was founded to dramatically improve patient outcomes by helping doctors optimize treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing better MRD testing for better clinical management and therapeutic development.
The difference
Why Haystack MRD
Confident MRD results
Transformative technology
Built by giants
Haystack Oncology was founded by pioneers in blood-based cancer diagnostics who were the first to envision a revolution in patient care made possible by groundbreaking molecular methods.
Packed with the power of Quest
Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless for easier, more streamlined patient care. Visit questdiagnostics.com to learn more.